Evidence map›Paper›PMID 31849719›Full record

ArticleFrontiers in psychiatry2019

Predictors of Outcomes in Adolescents With Clinical High Risk for Psychosis, Other Psychiatric Symptoms, and Psychosis: A Longitudinal Protocol Study.

Silvia Molteni, Eleonora Filosi, Maria Martina Mensi, Giulia Spada, Chiara Zandrini, Federica Ferro, Matteo Paoletti, Anna Pichiecchio, Ilaria Bonoldi, Umberto Balottin

Open access · goldAbstract read
In one paragraph

Article in Frontiers in psychiatry, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.7field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Neurocognition and functioning in adolescents at clinical high risk for psychosis.Child and adolescent psychiatry and mental health · 2023
    Article
  5. Article
  6. Article
  7. ITAlian partnership for psychosis prevention (ITAPP): Improving the mental health of young people.European psychiatry : the journal of the Association of European Psychiatrists · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 2 countries.

Silvia MolteniDepartment of Brain and Behavioral Sciences, University of Pavia, Pavia, Italy.
Eleonora FilosiChild Neuropsychiatry Unit, IRCCS Mondino Foundation, Pavia, Italy.
Maria Martina MensiDepartment of Brain and Behavioral Sciences, University of Pavia, Pavia, Italy.
Giulia SpadaInstitute of Psychiatry, Psychology and Neuroscience, King's College of London, London, United Kingdom.
Chiara ZandriniDepartment of Brain and Behavioral Sciences, University of Pavia, Pavia, Italy.
Federica FerroChild Neuropsychiatry Unit, IRCCS Mondino Foundation, Pavia, Italy.
Matteo PaolettiDepartment of Brain and Behavioral Sciences, University of Pavia, Pavia, Italy.
Anna PichiecchioDepartment of Brain and Behavioral Sciences, University of Pavia, Pavia, Italy.
Ilaria BonoldiDepartment of Brain and Behavioral Sciences, University of Pavia, Pavia, Italy.
Umberto BalottinDepartment of Brain and Behavioral Sciences, University of Pavia, Pavia, Italy.
University of Pavia · ITKing's College London · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In children and adolescents, schizophrenia is one of the ten main causes of disability-adjusted life years. The identification of people at Clinical High Risk of developing Psychosis (CHR-P) is one of the most promising strategies to improve outcomes. However, in children and adolescents research on the CHR-P state is still in its infancy and the clinical validity of at-risk criteria appears understudied in this population. Furthermore, only few studies have evaluated the psychopathological, neuropsychological, neuroimaging characteristics and, especially, long-term outcomes of adolescents at high risk. We present here the protocol of an innovative longitudinal cohort study of adolescents aged 12-17. The sample will consist of patients admitted to a third level neuropsychiatric unit, belonging to one of the following three subgroups: 1) adolescents with established Diagnostic and Statistical Manual of Mental Disorder-Fifth Edition psychosis, 2) adolescents with CHR-P, and 3) adolescents with psychiatric symptoms other than established psychosis or CHR-P. The primary aim of our study is to evaluate the 2-year prognosis across the three groups. We will measure transition to psychosis (or the stability of the diagnosis of psychosis in the psychotic group), the risk of development of other psychiatric disorders, as well as socio-occupational functioning at outcome. The secondary aim will be to explore the effect of specific predictors (clinical, neuropsychological and neuroimaging factors) on the prognosis. At baseline, 1-year and 2-year follow-up participants will be assessed using standardized semi-structured interviews and instruments. Psychopathological and functioning variables, as well as neuropsychological domains will be compared across the three subgroups. Moreover, at baseline and 2-year follow-up all recruited patients will undergo a 3-Tesla magnetic resonance imaging examination and diffusion tensor imaging parameters will be analyzed. We believe that this study will advance our ability to predict outcomes in underage CHR-P samples. In particular, our data will enable a better understanding of the clinical significance of CHR-P in adolescents, and shed new light on prognostic factors that can be used to refine the prediction of clinical outcomes and the implementation of preventive interventions.

Indexed as

adolescenceARMSattenuated psychosis syndromefunctioningprognosispsychosistransitionyoung people

Identifiers

PMID31849719
PMCPMC6902080
OpenAlexW2993185273

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.